Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kashiv BioSciences, LLC

Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
From Kashiv BioSciences, LLC
Via Business Wire
UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
From Kashiv Biosciences, LLC
Via Business Wire
Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Tickers AMRX
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
From Kashiv Biosciences, LLC
Via Business Wire
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
From Kashiv Biosciences, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.